Related by context. All words. (Click for frequent words.) 74 JAK inhibitor 72 neratinib 71 phase IIb clinical 71 pertuzumab 71 tanespimycin 70 SCH # 70 AEG# 70 PS# [001] 70 BAY #-# 70 Amrubicin 70 phase IIa clinical 70 investigational humanized monoclonal antibody 70 mTOR inhibitor 70 oral prodrug 70 PEG SN# 69 PRT# 69 lesinurad 69 Archexin 69 Panzem R 69 fosbretabulin 69 Azedra 69 orally administered inhibitor 69 sorafenib Nexavar 69 histone deacetylase HDAC inhibitor 69 alvespimycin 69 Alfimeprase 69 pan HDAC inhibitor 69 Factor VIIa 69 elotuzumab 69 CCX# 69 ocrelizumab 69 eprotirome 69 ixabepilone 69 axitinib 68 MAGE A3 ASCI 68 Tyrima 68 proteasome inhibitor 68 Xanafide 68 BRAF inhibitor 68 HCV protease inhibitor 68 BCX# 68 Tezampanel 68 thymalfasin 68 Radezolid 68 forodesine 68 HuMax EGFr 68 atacicept 68 lapatinib Tykerb 68 virus HCV protease inhibitor 68 pomalidomide 68 Carfilzomib 68 ganetespib 68 teriflunomide 68 CEQ# 68 IMA# 68 Dasatinib 68 PDE4 inhibitor 68 Targretin 68 Aurexis 68 Tanespimycin 68 ZACTIMA 68 cangrelor 67 Triolex 67 HGS ETR1 67 tezampanel 67 INCB# [001] 67 Dapagliflozin 67 metaglidasen 67 ZOLINZA 67 enzastaurin 67 Glufosfamide 67 Phenoptin 67 antiplatelet agent 67 Panzem R NCD 67 mertansine 67 CA4P 67 evaluating tivozanib 67 Valsartan 67 temsirolimus 67 Pivotal Phase III 67 MEK inhibitors 67 Cloretazine R VNP#M 67 HuLuc# 67 sorafenib tablets 67 Bezielle 67 Pharmacokinetics PK 67 selective androgen receptor modulator 67 gefitinib Iressa 67 ISIS # 67 Cardio Vascu Grow 67 XmAb# 67 TBC# 67 AEGR 67 MGCD# [001] 67 ENMD # 67 perifosine 67 Phase 2a trial 67 Onconase 67 figitumumab 67 ZYBRESTAT 67 Sym# 67 Panzem 67 orally bioavailable 67 Trofex 67 Traficet EN 67 Mipomersen 67 atrasentan 67 radiation sensitizer 67 sulodexide 67 brostallicin 67 sunitinib malate 67 lumiliximab 67 receptor tyrosine kinase inhibitor 67 novel VDA molecule 67 multicenter Phase III 67 Azedra TM 66 MGd 66 obatoclax 66 TELINTRA 66 Cleviprex TM clevidipine 66 fenofibric acid 66 Tarceva TM 66 Xcytrin R 66 mapatumumab 66 Phase Ib study 66 Ceflatonin 66 Phase 2b clinical 66 vosaroxin 66 FOLOTYN ® 66 LibiGel ® 66 Ambrisentan 66 CYC# 66 Nexavar ® 66 erlotinib Tarceva ® 66 IMC A# 66 ELACYT 66 Personalized Immunotherapy 66 bevacizumab Avastin ® 66 R#/MEM # 66 Amplimexon 66 Phase 2b clinical trials 66 Phase Ib 66 crizotinib PF # 66 EOquin TM 66 tamibarotene 66 cilengitide 66 REG1 66 HGS# 66 Aflibercept 66 PDX pralatrexate 66 otelixizumab 66 vinca alkaloid 66 EOquin 66 DB# [003] 66 Vandetanib 66 ularitide 66 Phase Ib clinical 66 HDAC Inhibitor 66 Azixa 66 Perifosine 66 vidofludimus 66 Safinamide 66 Troxatyl 66 dyskinesia PD LID 66 XL# XL# 66 preclinically 66 ZYBRESTAT fosbretabulin 66 vascular disrupting agent 66 PXD# 66 angiogenesis inhibitor 66 XYOTAX TM 66 OXi# 66 liposomal formulation 66 Vidaza azacitidine 66 TELCYTA 66 Bortezomib 66 Phase Ib II 66 belinostat 66 efficacy tolerability 66 epothilone 66 ongoing Phase 1b 66 multi kinase inhibitor 66 oral ridaforolimus 66 Pertuzumab 66 pharmacokinetics PK 66 histone deacetylase inhibitor 66 dacetuzumab 66 peginesatide 66 CR# vcMMAE 66 registrational trial 66 IRX 2 66 investigational monoclonal antibody 66 CYT# potent vascular disrupting 66 Phase Ib clinical trials 66 GAMMAGARD 66 Deforolimus 66 mGluR5 negative 66 Phase III Clinical Trial 66 BRIM2 66 Phase IIa trials 66 targeted radiotherapeutic 66 Tesetaxel 66 mipomersen 65 CRx 65 YONDELIS 65 Phase 1b trial 65 SinuNase TM 65 nab paclitaxel 65 sapacitabine 65 PSMA ADC 65 sargramostim 65 Ocrelizumab 65 SERMs 65 PANVAC VF 65 HGS ETR2 65 aflibercept 65 Proxinium TM 65 FOLFOX6 chemotherapy regimen 65 2 methoxyestradiol 65 seliciclib CYC# 65 antithrombotic 65 TACI Ig 65 alvimopan 65 glufosfamide 65 bevacizumab Avastin 65 cediranib 65 Vidofludimus 65 posaconazole 65 investigational drug 65 Vidaza R 65 VEGF Trap 65 Virulizin ® 65 Avanafil 65 Boceprevir 65 galiximab 65 Clolar ® 65 TNF Tumor Necrosis Factor 65 Asentar 65 Imprime PGG 65 PEGylated interferon beta 1a 65 epigenetic therapies 65 Irinotecan 65 anticancer compound 65 HCD# [002] 65 vascular disrupting agents 65 MDV# 65 Maribavir 65 NU# [001] 65 CRMD# 65 MEK inhibitor 65 TPI ASM8 65 Zybrestat 65 Myocet 65 Alzhemed TM 65 tafamidis 65 cetuximab Erbitux 65 Phase 2b Clinical Trial 65 Phase IIb clinical trials 65 dasatinib Sprycel ® 65 anticancer agent 65 Pruvel 65 vorinostat 65 Zolinza 65 Elagolix 65 CCR5 antagonist 65 gemcitabine Gemzar 65 Symadex 65 proteasome inhibitor bortezomib 65 Marqibo 65 visilizumab 65 hypoxia activated prodrug 65 intranasal formulation 65 Hsp# inhibitor 65 thalidomide Thalomid 65 6R BH4 65 TLK# 65 plasma kallikrein inhibitor 65 adecatumumab 65 Fx #A 65 Aclidinium 65 nucleoside analog 65 phase 2a 65 Aplidin 65 trastuzumab DM1 T DM1 65 pralatrexate 65 Vilazodone 65 BAL# [002] 65 Allovectin 7 R 65 Pimavanserin 65 Squalamine 65 MEK inhibitor RDEA# 65 investigational antiplatelet agent 65 Enzastaurin 65 phase IIb trial 65 ZYBRESTAT TM 65 Dacogen injection 65 Zoraxel TM 65 TG# [003] 65 deforolimus 65 Phase 2b study 65 vicriviroc 65 angiotensin receptor blocker ARB 65 Preclinical studies suggest 65 Phase IIa trial 65 Treanda 65 highly selective inhibitor 65 Zarnestra 65 Excellarate 65 Microplasmin 65 Rigel R# 65 INCB# [003] 65 GRN#L 65 systemically administered 65 HQK 65 pain palliation 65 NP2 Enkephalin 65 Eltrombopag 65 inhibitor RG# 65 direct thrombin inhibitors 65 Meets Primary Endpoint 65 delafloxacin 65 Zerenex 65 INCB# [002] 65 MKC# MKC# PP 65 VNP#M 65 CBLC# 65 Camptosar ® 65 REP# 65 reslizumab 65 vandetanib 65 PNP inhibitor 65 PSN# [002] 65 EFAPROXYN 64 tesmilifene 64 LymphoStat B 64 multicenter Phase II 64 trial evaluating PRX# 64 Pafuramidine 64 Phase 2a Clinical Trial 64 Excellarate TM 64 HuMax CD4 64 humanized monoclonal antibody 64 Neulasta ® 64 Stedivaze 64 OncoVEX GM CSF 64 Vicriviroc 64 Bucindolol 64 Genasense ® oblimersen 64 OvaRex R 64 lintuzumab 64 Pivotal Study 64 MYCAMINE 64 CoFactor 64 relapsed multiple myeloma 64 Bafetinib 64 aurora kinase 64 Varespladib 64 AAG geldanamycin analog 64 Cloretazine 64 AVE# 64 AVASTIN 64 interferon gamma 1b 64 Exelixis compounds 64 Gemzar ® 64 Eculizumab 64 mycophenolate mofetil 64 Pivotal Phase 64 custirsen 64 CIMZIA TM 64 dirucotide 64 HMG CoA reductase inhibitors 64 FUSILEV ® 64 panitumumab Vectibix 64 NEUGENE 64 PHX# 64 selective modulator 64 MAP# 64 Dalbavancin 64 HspE7 64 romiplostim 64 polymerase inhibitor 64 Arimoclomol 64 DU #b 64 SRT# [003] 64 PRTX 64 Exelixis XL# 64 LY# [003] 64 docetaxel Taxotere R 64 lomitapide 64 Cloretazine ® 64 tasocitinib 64 LEVADEX 64 CB2 selective receptor agonist 64 VAPRISOL 64 SARMs 64 LymphoStat B TM 64 humanized anti 64 RLY# 64 OncoVex 64 riociguat 64 iniparib 64 PEGylated Fab fragment 64 Vidaza ® 64 faropenem 64 eltrombopag 64 bafetinib 64 Phase 1b 64 ALN PCS 64 imatinib Gleevec ® 64 varespladib 64 GLPG# 64 Phase #b/#a trial 64 CTAP# Capsules 64 Methylnaltrexone 64 HuMax CD# 64 ponatinib 64 metastatic castration resistant 64 cancer immunotherapies 64 darapladib 64 teduglutide 64 Bazedoxifene 64 Trastuzumab 64 Phase IIIb 64 potent inhibitor 64 Phase #/#a trial 64 alkylating agent 64 volociximab 64 XL# XL# XL# XL# 64 CD3 monoclonal antibody 64 eniluracil 64 KRN# 64 myelofibrosis polycythemia vera 64 terlipressin 64 tipifarnib 64 TKM ApoB 64 Apoptone 64 phase Ib 64 tiapamil 64 investigational hepatitis C 64 PLK1 SNALP 64 PF # [001] 64 incyclinide 64 SinuNase 64 OMP #M# 64 XL# anticancer compounds 64 proteasome inhibitors 64 non nucleoside inhibitor 64 lintuzumab SGN 64 CDK inhibitor 64 GVAX 64 endothelin receptor antagonists 64 Phase #b/#a 64 muraglitazar 64 Pralatrexate 64 ThermoDox R 64 XL# XL# XL# 64 beta 1a 64 MAXY G# 64 INTEGRILIN 64 Corlux 64 Fibrillex TM 64 Bicifadine 64 XL# [003] 64 NVA# 64 Bevacizumab 64 TRO# 64 AQ4N 64 catheter occlusion 64 cetuximab Erbitux R 64 Amigal 64 Fludara ® 64 bortezomib Velcade R 64 Angiocept 64 Leukine ® 64 oral Janus kinase 64 eculizumab 64 HER2 positive metastatic breast 64 regorafenib 64 favorable pharmacokinetic profile 64 APEX PD 64 novel histone deacetylase 64 oral antiviral 64 Phase III clinical 64 UPLYSO 64 Ranolazine 64 Sapacitabine 64 davunetide intranasal AL 64 IL# PE#QQR 64 tigecycline 64 GRNCM1 64 Hsp# Inhibitor 64 ostarine 64 Ostarine 64 sunitinib Sutent ® 64 DFMO 64 phase IIb study 64 tremelimumab 64 entinostat 64 Seliciclib 64 TH# [003] 64 RSD# 64 Azedra ™ 64 romidepsin 64 refractory gout 64 celgosivir 64 DAVANAT 64 novel oral anticoagulant 64 metastatic HRPC 64 Civacir 64 Interferon alpha 64 selective adenosine 64 delta isoform 64 Apixaban 64 Annamycin 64 pharmacokinetics pharmacodynamics 64 Onco TCS 64 GSK# [002] 64 INT# [002] 64 rFVIIa 64 Romidepsin 64 Desmoteplase 64 Aliskiren 64 cancer neuroendocrine tumor 63 Augment TM 63 aspirin clopidogrel 63 Nuvion 63 echinocandin 63 cobiprostone 63 PKC# 63 bardoxolone 63 motesanib 63 phase IIb 63 NGX# 63 Inhalation Solution 63 JAK Inhibitor 63 Teriflunomide 63 IMiDs R 63 Ophena TM 63 decitabine 63 Temsirolimus 63 velafermin 63 octreotide acetate 63 CYT# 63 elacytarabine 63 herpetic keratitis 63 oral picoplatin 63 xanthine oxidase inhibitor 63 MyVax R 63 Dacogen decitabine 63 oral rivaroxaban 63 ALN TTR 63 Lenocta 63 DXL# 63 kinase inhibitor 63 subcutaneous formulation 63 therapeutic monoclonal antibody 63 Virulizin R 63 CD# monoclonal antibody 63 GEM OS2 63 lixisenatide 63 midstage clinical trials 63 acyclovir Lauriad R 63 FASLODEX 63 ELND# 63 HDAC inhibitor 63 vemurafenib 63 Muraglitazar 63 Fulvestrant 63 preclinical efficacy 63 Octreolin 63 docetaxel chemotherapy 63 Xeloda ® 63 Oral NKTR 63 MOZOBIL 63 PROMACTA 63 LEVADEX ™ 63 Randomized Phase 63 Darusentan 63 Degarelix 63 dose escalation trial 63 Xinlay 63 Xelox 63 Reverset 63 velafermin belinostat 63 selective androgen receptor modulators 63 EndoTAG TM -1 63 CD# CEA 63 ATL# [002] 63 selective antagonist 63 LEUKINE 63 oral proteasome inhibitor 63 squalamine 63 TREANDA 63 Ridaforolimus 63 RG# [001] 63 sodium glucose cotransporter 63 Trofex TM 63 Ozarelix 63 2 inhibitor CYT# 63 Phase 1a clinical 63 Aurora kinase 63 LEP ETU 63 opioid induced bowel dysfunction 63 Viprinex 63 acute peripheral arterial 63 Elesclomol 63 Ixempra 63 Tarvacin TM 63 THR beta agonist 63 safety tolerability pharmacokinetic 63 talactoferrin 63 Epratuzumab 63 pegfilgrastim 63 metastatic colorectal 63 ocular formulation 63 ALN TTR# 63 antiangiogenic agent 63 urate lowering 63 Zenvia Phase III 63 brivaracetam 63 Romiplostim 63 factor Xa 63 OvaRex ® MAb 63 amrubicin 63 torezolid phosphate 63 teplizumab 63 methylnaltrexone bromide 63 AZD# 63 veltuzumab 63 Serdaxin 63 standard chemotherapy regimen 63 ALKS 63 Alocrest 63 Debio 63 ARIKACE ™ 63 long acting muscarinic 63 PREOS 63 APTIVUS 63 TORISEL 63 refractory chronic lymphocytic 63 pradefovir 63 IMiD 63 Laquinimod 63 cathepsin K inhibitor 63 ospemifene 63 ANYARA 63 Omacetaxine 63 Cetrorelix 63 Phase 1b clinical 63 metastatic hormone refractory 63 Phase 2a 63 pegylated interferons 63 Elotuzumab 63 dextromethorphan quinidine 63 boosted protease inhibitor 63 darusentan 63 DOS# 63 Phase #b/#a clinical 63 TREDAPTIVE 63 Losartan 63 bicifadine 63 Avastin bevacizumab 63 Pirfenidone 63 CD# antibody [001] 63 topically applied SEPA 63 anidulafungin 63 occlusion PAO 63 Fodosine 63 HoFH 63 GW# [003] 63 personalized immunotherapy 63 Parkinson disease levodopa induced 63 SUTENT ® 63 MGN# 63 talabostat 63 Phase 2a clinical 63 investigational compounds 63 AZILECT R 63 Cloretazine R 63 candesartan cilexetil 63 Urocidin 63 Telavancin 63 adalimumab Humira 63 fluvastatin 63 Iluvien ® 63 tramiprosate Alzhemed TM 63 edifoligide 63 rosuvastatin #mg 63 ON #.Na 63 Pemetrexed 63 phase IIa 63 alfimeprase 63 registrational 63 chemopreventive agent 63 RG# ITMN 63 castrate resistant prostate cancer 63 Curaxin CBLC# 63 elesclomol 63 ZD# [001] 63 generation purine nucleoside 63 chemotherapy induced neutropenia 63 indibulin 63 mitogen activated ERK kinase 63 RhuDex ® 63 PI3K/Akt pathway inhibitor 63 Triapine R 63 Phase III Pivotal 63 PCK# 63 ThermoDox ® clinical 63 exemestane Aromasin 63 Serdaxin ® 63 lenalidomide Revlimid 63 solithromycin 63 Zorbtive TM 63 Phase IIb Clinical Trial 63 Synavive 63 IAP inhibitor 63 bortezomib Velcade 63 nitazoxanide 63 OMP #R# 63 EP #R 63 MYDICAR ® 63 Voreloxin 63 signal transduction inhibitor 63 ARC# [002] 63 Capesaris 63 PEG PAL 63 rHuPH# 63 pan histone deacetylase 63 ADVEXIN 63 AMD# [003] 63 ATACAND 63 Phase 1b clinical trials 63 pivotal Phase III 63 trastuzumab Herceptin 63 drug ISA# 63 TLR8 agonist 63 picoplatin 63 CCR5 inhibitor 63 pharmacodynamic properties 63 Navelbine ® 63 Blinatumomab 63 CCX# B 63 unique alkylating agent 63 CORT # 63 antisense drug 63 ruxolitinib 63 LymphoStat B belimumab 63 ridaforolimus 63 immune modulator 63 Peginterferon 63 voreloxin 63 Candesartan 63 huC# DM4 63 ritonavir boosted 63 monoclonal antibody conjugated 63 TYZEKA 62 ICA # 62 PI3K/mTOR 62 Androxal TM 62 assessing T DM1 62 Allovectin 7 62 JAK2 inhibitor 62 immunomodulating 62 iclaprim 62 drug figitumumab 62 palifosfamide 62 Exherin TM 62 FOLOTYN 62 ONCONASE R 62 seliciclib 62 Phase 2b trial 62 Hsp# inhibitors 62 LibiGel Phase III 62 Phase III Clinical Trials 62 Vaprisol 62 midstage clinical 62 AzaSite Xtra 62 severe gastroparesis 62 Pradefovir 62 Exemestane 62 NATRECOR ® 62 relapsed refractory multiple myeloma 62 NeuroSTAT ® 62 SUTENT 62 Tavocept 62 NOX E# 62 pioglitazone HCl 62 direct renin inhibitor 62 Phase IIb clinical 62 Velcade bortezomib 62 non alcoholic steatohepatitis 62 oxypurinol 62 Actilon 62 ALN HPN 62 AP# [003] 62 Panzem NCD 62 Acapodene 62 alemtuzumab Campath 62 Shigamabs ® 62 EGFR HER2 62 LAF# 62 trastuzumab Herceptin R 62 PD LID 62 Sudhir Agrawal D.Phil 62 epothilones 62 relapsed MM 62 Akt inhibitor 62 paclitaxel Taxol 62 dexpramipexole 62 abatacept Orencia 62 NOXAFIL 62 zanolimumab 62 RoACTEMRA 62 Rebif ® 62 docetaxel Taxotere ® 62 daclizumab 62 Medoxomil 62 ATL# [001] 62 oral nucleoside analogue 62 Tasimelteon 62 insulin sensitizers 62 Chemophase 62 NV1FGF 62 dose cohorts 62 calcineurin inhibitors 62 S/GSK# 62 Hematide ™ 62 Nasulin 62 ataluren 62 factor Xa inhibitors 62 Icatibant 62 investigational compound 62 GMX# 62 selective estrogen receptor modulator 62 TNFerade 62 tubulin inhibitor 62 BZL# 62 Vicinium TM 62 investigational therapies 62 HCV protease 62 IV Busulfex 62 Zoraxel 62 Tolerability 62 Polymer Microspheres 62 LY# [002] 62 RELOVAIR ™ 62 ThermoDox ® 62 RGB # 62 RSR# 62 OHR/AVR# 62 DR Cysteamine 62 Lisofylline LSF 62 sodium Injection 62 BLP# Liposome Vaccine 62 INSPIRE Trial Phase III 62 radezolid 62 alfa 2a 62 HSP# inhibitor 62 Phase IIb Trial 62 ToGA 62 bosutinib 62 Viramidine 62 acetonide FA 62 5 FU leucovorin 62 azacitidine 62 CYP#A# CYP#D# 62 Talabostat 62 immunomodulatory therapy 62 molecular imaging radiopharmaceutical 62 Ramoplanin 62 bendamustine 62 olmesartan 62 PrevOnco ™ 62 protein kinase inhibitor 62 Phase IIIb clinical 62 cannabinor 62 tecarfarin 62 RDEA# 62 Denosumab 62 Bendavia 62 MKC# MT 62 Afatinib 62 immunotherapeutic agent 62 AKT inhibitor 62 small molecule activators 62 WX UK1 62 Insegia 62 Vectibix 62 Cabazitaxel 62 Ceflatonin R 62 Doxil ® 62 compound INCB# 62 PrevOnco 62 Adenoma Prevention 62 Rosuvastatin 62 PARP inhibitor 62 ASA# 62 panitumumab 62 sipuleucel T 62 angiotensin II receptor blocker 62 ILUVIEN ® 62 INC# 62 erlotinib Tarceva 62 Solazed TM 62 selective kinase inhibitor 62 ritonavir boosted danoprevir 62 eplerenone 62 mRCC 62 oral Xeloda 62 MT# MEDI 62 tyrosine kinase inhibitor 62 Cethromycin 62 K ras mutations 62 renin inhibitors 62 microtubule inhibitor 62 Natalizumab 62 selective inhibition 62 investigational pharmacologically unique 62 phase III isavuconazole 62 Pyridorin 62 cariprazine 62 sitaxsentan 62 Campath ® 62 GALNS 62 JAK1 62 generation Hsp# inhibitor 62 5 fluorouracil leucovorin 62 StemEx 62 platelet inhibitor 62 Doxil 62 valsartan 62 Taxotere ® 62 FLT3 62 Marqibo TM 62 mecamylamine 62 MEK Inhibitor 62 Prospective Randomized 62 Actimmune ® 62 lexidronam injection 62 Prostate AdenoCarcinoma Treatment 62 Completes Patient Enrollment 62 Nanobody ® 62 sunitinib Sutent 62 oral anticoagulant 62 EGS# 62 oncolytic virus therapies 62 Fludara 62 peptibody 62 aflibercept VEGF Trap 62 Combo Stent 62 Leukine 62 IMiDs 62 oral dual endothelin 62 apixaban 62 HCV polymerase inhibitors 62 Omigard 62 investigational protease inhibitor 62 Epanova 62 Dabigatran etexilate 62 Erbitux cetuximab 62 Golimumab 62 apaziquone 62 Sphingomab TM 62 histone deacetylase HDAC 62 cetuximab Erbitux ® 62 combretastatin A4 phosphate CA4P 62 Investigational Drug 62 CTLA4 Ig 62 Nanobody 62 hypoxia selective 62 non nucleoside 62 ARCOXIA 62 recurrent glioblastoma multiforme 62 Belinostat 62 NPC 1C 62 ISENTRESS 62 midstage trials 62 tramiprosate 62 neuroprotectant 62 SomatoKine 62 valopicitabine 62 Cysteamine 62 KNS # 62 FOLFOX chemotherapy 62 Factor Xa inhibitor 62 delivers fluocinolone acetonide FA 62 midstage studies 62 NPM1 62 JAK inhibitors 62 Specifid 62 GV# [001] 62 aldehyde dehydrogenase ALDH2 deficiency 62 Fondaparinux 62 pharmacokinetic PK 62 paclitaxel Taxol ® 62 sodium thiosulfate STS 62 Azacitidine 62 TAFA#